Business
Shattuck Labs Announces Participation in Upcoming March Investor Conferences
AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences: Conference Details TD Cowen 46th Annual Health C
About this update from Shattuck Labs, Inc.
[{"type":"image","alt":"Shattuck Labs, Inc.","displaySize":"","headline":null,"caption":"Shattuck Labs, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":69,"url":"https://media.zenfs.com/en/globenewswire.com/b5ea3fb4ff3f25592a62a57f48a4f2e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o_.4r1lpCFq8StfajNT2qg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b5ea3fb4ff3f25592a62a57f48a4f2e8","width":300,"height":69}},"lazy":false},{"type":"text","content":"AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences:","length":451,"tagName":"p"},{"type":"text","content":"Conference Details","length":18,"tagName":"p"},{"type":"text","content":"TD Cowen 46th Annual Health Care Conference","length":43,"tagName":"p"},{"type":"text","content":"Format: Corporate presentation and one-on-one meetings Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive OfficerPresentation Date: March 2, 2026Time: 9:10 AM ETLocation: Boston, MAWebcast link: HERE","length":211,"tagName":"p"},{"type":"text","content":"Leerink Partners 2026 Global Health Care Conference","length":51,"tagName":"p"},{"type":"text","content":"Format: One-on-one investor meetings Participant: Taylor Schreiber, M.D., Ph.D., Chief Executive OfficerDates: March 10-11, 2026Location: Miami, FL","length":150,"tagName":"p"},{"type":"text","content":"Interested parties can access live audio webcasts of these presentations via the Investor Relations section of the company’s website at www.shattucklabs.com. Replay webcasts will be available for approximately 30 days following the live presentations.","length":251,"tagName":"p"},{"type":"text","content":"About SL-325SL-325 is a potentially first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck’s preclinical studies demonstrate high affinity binding and superior activity over TL1A...